Replies to post #544528 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Larppis,

I guess the question then is how many might have received a checkpoint inhibitor at some point during the course of this older trial which of course could have been the precipitating factor for the Keytruda combo trial vs DCVax-L and Poly ICLC alone which started much later. Best wishes.

[beartrap12]

Larppis, thanks for the update on the poly ICLC trial.

The Poly-ICLC trial has been going for 12 years now: https://clinicaltrials.gov/ct2/show/NCT01204684
The slide we've seen showed 50% survival rate at 100 months. And I believe ATLinsider said he's seen a More recent one showing 50% at 120 months.

Looks like vaccine+Keytruda is better with about 60% survival at 2 years and median not reached.

Now let’s see what vaccine+Keytruda +poly ICLC or another adjuvant can do to that efficacy rate!

Cure for most? Just wondering…

[CaptainObvious]

From looking at the trial, do we know how many are GBM, and how many of the GBM are included in the 60%? Looks like they are allowing other types of gliomas

Inclusion Criteria

Patients with newly diagnosed or recurrent glioma of WHO Grade III or IV {anaplastic astrocytoma (AA), anaplastic astro-oligodendroglioma (AO), or glioblastoma (GBM)} will be eligible for this protocol.